drugset / Trial / NCT04101383
A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients
RandomizedCrossoverQuadruple-blindBasic science
Summary
Pharmacokinetics and pharmacodynamics study of 2 formulation of insulin glargine (RinGlar® GEROPHARM vers. Lantus® Sanofi-Aventis)
Timeline
- Start
- 2017-10-16
- Primary completion
- 2018-02-16
- Completion
- 2018-02-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RinGlar® | Unknown | 0.6 iu/kg | Subcutaneous |
| Comparator | insulin glargine | Protein / enzyme biologic | 0.6 iu/kg | Subcutaneous |
Indications
No indication recorded.